Educational note: This article is provided for general educational purposes only. It is not medical advice and is not intended to diagnose, treat, cure, or prevent any disease. Readers should speak with their neurologist or physician before making any decisions related to their health or care.
The endocannabinoid system, often abbreviated as the ECS, is a signaling network found throughout the human body, including the brain and peripheral nervous system. It was identified by researchers studying how cannabis compounds act on the body, and it turned out to be a system the body produces and uses on its own, independent of any external substance. Understanding the ECS requires no prior background in pharmacology. At its simplest, it is a communication system built from three parts: naturally occurring signaling molecules, the receptors those molecules act on, and the enzymes that build and break those molecules down. This article walks through how the ECS was discovered, what its core components are, where its receptors are located in the body, and what general physiological roles it appears to play.
How the Endocannabinoid System Was Discovered
The ECS was not identified all at once. It emerged over roughly five years of laboratory work in the late twentieth century, as separate research groups pieced together how cannabis compounds produced their effects at the molecular level.
The first major milestone came in 1990, when a research team led by Lisa Matsuda cloned a complementary DNA sequence encoding a previously unknown G protein-coupled receptor in rat brain tissue. When this receptor was expressed in cells, it responded to cannabinoid compounds, confirming that a specific receptor for these substances existed in the brain. This receptor became known as CB1, and its messenger RNA was found concentrated in regions such as the basal ganglia, hippocampus, and cerebellar cortex [1]. Two years later, in 1992, a research group at Hebrew University in Jerusalem, working with William Devane, Lumír Hanuš, and Raphael Mechoulam, isolated a compound from pig brain tissue that bound to this same receptor. They named the compound anandamide, from the Sanskrit word for bliss, and it became the first endogenous, or naturally produced, ligand identified for the cannabinoid receptor [2].
In 1993, a separate team led by Sean Munro cloned a second cannabinoid receptor from a human promyelocytic cell line. This receptor, called CB2, was found predominantly outside the brain, particularly in tissues associated with the immune system such as the spleen, which led to its early characterization as the "peripheral" cannabinoid receptor [3]. Two years after that, in 1995, Mechoulam's group, in collaboration with Shimon Ben-Shabat and colleagues, isolated a second endogenous ligand, 2-arachidonoylglycerol, or 2-AG, from canine gut tissue. This molecule bound to both CB1 and CB2 receptors and was later recognized as the more abundant of the two endocannabinoids in the central nervous system [4]. Together, these discoveries, spanning the cloning of two receptors and the identification of two endogenous ligands, established the ECS as a distinct signaling system with its own molecular architecture.
The Three Core Components of the ECS
Researchers generally describe the ECS as having three interdependent parts.
The first component is the endocannabinoids themselves, chiefly anandamide and 2-AG. Unlike many signaling molecules in the body, endocannabinoids are not stored in advance inside cells. Instead, they are synthesized from lipid precursors in cell membranes on demand, released when needed, and then broken down shortly afterward. This "on-demand" production is a distinguishing feature of the system.
The second component is the cannabinoid receptors, primarily CB1 and CB2, though additional receptors and channels are sometimes considered part of a broader "endocannabinoidome." Both CB1 and CB2 are G protein-coupled receptors, meaning that when activated, they trigger a cascade of changes inside the cell rather than directly opening a channel or acting as an enzyme themselves.
The third component is the set of metabolic enzymes responsible for producing and degrading endocannabinoids. Anandamide is broken down primarily by an enzyme called fatty acid amide hydrolase, or FAAH, while 2-AG is broken down primarily by monoacylglycerol lipase, or MAGL. These enzymes act quickly, which is consistent with the transient, localized nature of endocannabinoid signaling; a molecule is produced, acts briefly on nearby receptors, and is then cleared [5]. Synthesis is handled by other enzymes, including diacylglycerol lipase for 2-AG, working in the opposite direction of FAAH and MAGL.
Where CB1 and CB2 Receptors Are Found
CB1 receptors are among the most abundant G protein-coupled receptors in the mammalian central nervous system. They are especially dense in the cortex, hippocampus, basal ganglia, cerebellum, and hypothalamus, regions involved in memory, movement coordination, and appetite regulation, respectively. Within the nervous system, CB1 receptors are predominantly located on presynaptic nerve terminals, positioning them to influence the release of other neurotransmitters rather than to directly generate an electrical signal themselves. CB1 receptors are also present, at lower density, in peripheral tissues such as skeletal muscle, the liver, and adipose tissue [6].
CB2 receptors have a largely different distribution. They were first characterized in immune tissue, including the spleen and circulating immune cells, which is why they were originally labeled the peripheral cannabinoid receptor. Subsequent research has found that CB2 receptors are also present in the central nervous system, including on microglia, the resident immune cells of the brain, and in smaller amounts on certain neurons, though generally at much lower density than CB1 [3][6]. Because of this distribution, CB1 is typically discussed in the context of neuronal signaling, while CB2 is more often discussed in relation to immune and inflammatory processes, although this distinction is not absolute and continues to be refined as research methods improve.
General Physiological Roles of the ECS
One of the most studied functions of the ECS at the level of individual brain cells is retrograde signaling at synapses. In a typical synapse, chemical signals travel in one direction, from a presynaptic neuron to a postsynaptic neuron. Endocannabinoid signaling works in reverse. When a postsynaptic neuron is activated, it can synthesize endocannabinoids on demand and release them so that they diffuse backward across the synaptic gap to activate CB1 receptors on the presynaptic terminal. This activation typically suppresses further release of neurotransmitters such as glutamate or GABA from that presynaptic terminal, for a period ranging from a fraction of a second to, in some circumstances, much longer. This mechanism allows a neuron to influence its own upstream input, providing a form of feedback that is thought to contribute to synaptic plasticity, meaning the strengthening or weakening of connections between neurons over time [7].
Beyond this synaptic role, the ECS is frequently described in the research literature as a homeostatic system, meaning one broadly involved in helping maintain physiological balance across multiple body systems. It has been studied in connection with the regulation of mood, appetite, sleep, pain processing, motor control, and immune function, largely because CB1 and CB2 receptors are positioned at key points within the circuits that govern these processes. It is worth noting that "involved in regulation" is a general statement about where the system's receptors sit within these circuits; it is not a claim that manipulating the ECS produces a specific clinical benefit for any particular condition.
Why the ECS Interests Neurological Researchers
Because CB1 receptors are so densely represented in brain regions tied to movement and coordination, and because CB2 receptors are tied to the brain's immune and inflammatory signaling through microglia, the endocannabinoid system continues to be an active area of investigation within neurological research generally, including in the study of movement disorders [8]. At this stage, this interest reflects the biology of where the system's receptors are located and what processes they appear to touch, not a conclusion about outcomes for any specific condition. Readers interested in how this general research connects to Parkinson's disease specifically can find that discussion covered in a separate, dedicated article on this site.
Closing Note
The endocannabinoid system is, at its core, a naturally occurring signaling network built from endogenous ligands, receptors, and the enzymes that regulate them. Its discovery reshaped the way researchers understand a class of receptors first identified through the study of cannabis, and decades of subsequent work have mapped its distribution and its role in everyday neuronal communication in considerable detail. As with any area of active scientific inquiry, understanding continues to evolve, and readers are encouraged to view this overview as a foundation for further learning rather than a complete or final account.
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified neurologist or physician regarding any questions about a medical condition or before making changes related to your health or treatment plan.
References
Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346(6284):561-564. https://pubmed.ncbi.nlm.nih.gov/2165569/
Devane WA, Hanuš L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946-1949. https://pubmed.ncbi.nlm.nih.gov/1470919/
Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61-65. https://www.nature.com/articles/365061a0
Mechoulam R, Ben-Shabat S, Hanuš L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology. 1995;50(1):83-90. https://pubmed.ncbi.nlm.nih.gov/7605349/
van Egmond N, Straub VM, van der Stelt M. Targeting endocannabinoid signaling: FAAH and MAG lipase inhibitors. Annual Review of Pharmacology and Toxicology. 2021;61:441-463. https://www.annualreviews.org/doi/10.1146/annurev-pharmtox-030220-112741
Svízenská I, Dubový P, Šulcová A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures: a short review. Pharmacology Biochemistry and Behavior. 2008;90(4):501-511. https://pubmed.ncbi.nlm.nih.gov/18584858/
Castillo PE, Younts TJ, Chávez AE, Hashimotodani Y. Endocannabinoid signaling and synaptic function. Neuron. 2012;76(1):70-81. https://pubmed.ncbi.nlm.nih.gov/23040807/
Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nature Reviews Neurology. 2020;16(1):9-29. https://www.nature.com/articles/s41582-019-0284-z